Redefining the Treatment of Squamous Cell Carcinoma of the Anal Canal (SCAC) | ZYNYZ® (retifanlimab-dlwr) The First and Only FDA-Approved PD-1 Inhibitor for Adults with Inoperable Locally Recurrent or Metastatic SCAC

Event Date:

Mar 25, 2026

Credit Type:

--

Credits:

--